Olezarsen Fast Tracked for Familial Chylomicronemia Syndrome
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Olezarsen is an investigational LICA antisense medication designed to inhibit the production of apoC-III for patients at risk of disease due to elevated triglyceride levels.
Further, baseline vitamin D-related biomarkers lower for individuals with higher BMI
Increase of one daily meal associated with average difference in annual weight change of 0.28 kg
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Weight loss pharmacotherapy recommended as adjunct to health behavior and lifestyle treatment in children 12 years and older with obesity
Risk evaluation and mitigation strategy updated for abortion pill, mifepristone; Potential PTSD therapy shows positive results; A host of HIV meds are to be discontinued in the next year; Weight-loss treatment gains expanded approval in pediatrics; Experts rank their best diets for a variety of categories.
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
The application was approved through the FDA’s 505(b)(2) regulatory pathway.
Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 designed to modulate heme biosynthesis by limiting glycine uptake.